Cobolimab in combination with dostarlimab and docetaxel is in clinical development for the treatment of advanced non-small cell lung cancer (NSCLC) in patients who have progressed on prior treatment with anti-PD-L1 therapy and chemotherapy. NSCLC is the most common type of lung cancer. Symptoms include a cough, repeated chest infections, breathlessness, unexplained pain, weight loss or tiredness. Cobolimab and dostarlimab combined has the potential to improve anti-tumour immunity.
Cobolimab with dostarlimab and docetaxel for advanced non-small-cell lung cancer after anti-PD-L1 therapy and chemotherapy
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Patients-Public_Motifs_Conduction-broadcasting_RGB-scaled_edit1233.jpg)
Cobolimab in combination with dostarlimab and docetaxel is in clinical development for the treatment of advanced non-small cell lung cancer (NSCLC) in patients who have progressed on prior treatment with anti-PD-L1 therapy and chemotherapy
Interventions:
Cobolimab
, Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous)
, Dostarlimab (TSR-042; Jemperli)
Indications:
Non-small-cell lung cancer (NSCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2023